Time to normalisation of C-reactive protein and incidence of relapse in microscopic polyangiitis: A medical records review study in Japan

被引:1
|
作者
Yamaguchi, Makoto [1 ]
Ito, Mayumi [1 ]
Sugiyama, Hirokazu [1 ]
Iwagaitsu, Shiho [1 ]
Nobata, Hironobu [1 ]
Kinashi, Hiroshi [1 ]
Katsuno, Takayuki [1 ,2 ]
Ando, Masahiko [3 ]
Kubo, Yoko [4 ]
Banno, Shogo [1 ]
Ito, Yasuhiko [1 ]
Ishimoto, Takuji [1 ,5 ]
机构
[1] Aichi Med Univ, Dept Nephrol & Rheumatol, Nagakute, Aichi, Japan
[2] Aichi Med Univ, Dept Nephrol & Rheumatol, Med Ctr, Okazaki, Aichi, Japan
[3] Nagoya Univ Hosp, Data Coordinating Ctr, Dept Adv Med, Nagoya, Japan
[4] Nagoya Univ, Grad Sch Med, Dept Prevent Med, Nagoya, Japan
[5] Aichi Med Univ, Dept Nephrol & Rheumatol, 1-1 Karimata, Yazako, Nagakute 4801195, Japan
关键词
Antineutrophil cytoplasmic antibody; antineutrophil cytoplasmic antibody-associated vasculitis; C-reactive protein; microscopic polyangiitis; relapse; AUTOANTIBODY-ASSOCIATED VASCULITIS; ANCA-ASSOCIATED VASCULITIS; MORTALITY; PREDICTORS;
D O I
10.1093/mr/roac146
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Despite the identification of risk factors for relapses in antineutrophil cytoplasmic antibody-associated vasculitis, the relationship between changes in C-reactive protein (CRP) levels after the initial treatment and the incidence of relapse remains unknown. This study aimed to assess the association between the time taken for normalisation of CRP levels and the incidence of relapse in Japanese adult patients with microscopic polyangiitis. Methods This study included 85 consecutive patients with newly diagnosed microscopic polyangiitis who achieved remission after 6 months of immunosuppressive treatment at the Aichi Medical University Hospital between 2009 and 2017. The relationship between the time to normalisation of CRP after the initial immunosuppressive treatment and relapse incidences was evaluated using multivariable Cox proportional hazard models. Results During the follow-up period, 13 (30.2%), 7 (41.2%), and 16 (64.0%) patients relapsed (P = .025) within 1-14, 15-28, and >= 29 days of normalisation, respectively. The hazard ratios [95% confidence intervals (CIs)] for the time to normalisation of CRP of 1-14, 15-28, and >= 29 days were 1.00 (reference), 2.42 (95% CI: 0.92-6.39), and 3.48 (95% CI: 1.56-7.76), respectively. Conclusions A significant association between the time to normalisation of CRP and the relapse incidence in Japanese patients with microscopic polyangiitis was observed.
引用
收藏
页码:151 / 156
页数:6
相关论文
共 50 条
  • [31] Increased serum C-reactive protein is a potent independent predictor of stroke and death in men but not in women: a community-based study in northern Japan
    Satoh, K.
    Tanaka, F.
    Onoda, T.
    Kawamura, K.
    Itai, K.
    Sakata, K.
    Okayama, A.
    Nakamura, M.
    EUROPEAN HEART JOURNAL, 2006, 27 : 307 - 308
  • [32] Pitavastatin reduced C-reactive protein without increasing the incidence of diabetes in Japanese individuals with impaired glucose tolerance (J-PREDICT study)
    Odawara, M.
    Yamazaki, T.
    Kishimoto, J.
    Ito, C.
    Noda, M.
    Terauchi, Y.
    Shiba, T.
    Iwamoto, Y.
    Akanuma, Y.
    Kadowaki, T.
    EUROPEAN HEART JOURNAL, 2014, 35 : 392 - 392
  • [33] High-Sensitivity C-Reactive Protein Discordance With Atherogenic Lipid Measures and Incidence of Atherosclerotic Cardiovascular Disease in Primary Prevention: The ARIC Study
    Quispe, Renato
    Michos, Erin D.
    Martin, Seth S.
    Puri, Rishi
    Toth, Peter P.
    Al Suwaidi, Jassim
    Banach, Maciej
    Virani, Salim S.
    Blumenthal, Roger S.
    Jones, Steven R.
    Elshazly, Mohamed B.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2020, 9 (03):
  • [34] Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study
    Otani, T
    Iwasaki, M
    Sasazuki, S
    Inoue, M
    Tsugane, S
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (04) : 690 - 695
  • [35] Influence of Leisure-Time Physical Activity on the Relationship between C-Reactive Protein and Hypertension in a Community-Based Elderly Population of Japan: The Tsurugaya Project
    Kaijun Niu
    Atsushi Hozawa
    Kazuki Fujita
    Kaori Ohmori
    Mitsuharu Okutsu
    Shinichi Kuriyama
    Ichiro Tsuji
    Ryoichi Nagatomi
    Hypertension Research, 2005, 28 : 747 - 754
  • [36] Influence of leisure-time physical activity on the relationship between C-reactive protein and hypertension in a community-based elderly population of Japan: The Tsurugaya Project
    Niu, K
    Hozawa, A
    Fujita, K
    Ohmori, K
    Okutsu, M
    Kuriyama, S
    Tsuji, I
    Nagatomi, R
    HYPERTENSION RESEARCH, 2005, 28 (09) : 747 - 754
  • [37] Letter to "C-reactive protein level predicts need for medical intervention in pregnant women with SARS-CoV2 infection: A retrospective study"
    Saito, Yoshihiro
    Umazume, Takeshi
    Watari, Hidemichi
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2022, 48 (05) : 1285 - 1286
  • [38] CLINICAL SIGNIFICANCE OF SERUM C-REACTIVE PROTEIN LEVELS FOR PREDICTING LENVATINIB-TREATED UNRESECTABLE HEPATOCELLULAR CARCINOMA: A MULTI-INSTITUTIONAL STUDY IN JAPAN
    Okumura, Taiki
    Kimura, Takefumi
    Iwadare, Takanobu
    Kobayashi, Hiroyuki
    Wakabayashi, Syun-ichi
    Yamashita, Yuki
    Umemura, Takeji
    GASTROENTEROLOGY, 2024, 166 (05) : S1723 - S1724
  • [39] Prognostic value of neutrophil-lymphocyte ratio and level of C-reactive protein in a large cohort of pancreatic cancer patients: a retrospective study in a single institute in Japan
    Inoue, Dai
    Ozaka, Masato
    Matsuyama, Masato
    Yamada, Ikuhiro
    Takano, Koichi
    Saiura, Akio
    Ishii, Hiroshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (01) : 61 - 66
  • [40] Does C-reactive protein to serum Albumin Ratio correlate with diabEtic nephropathy in patients with Type 2 dIabetes MEllitus? The CARE TIME study
    Bilgin, Satilmis
    Kurtkulagi, Ozge
    Tel, Burcin Meryem Atak
    Duman, Tuba Taslamacioglu
    Kahveci, Gizem
    Khalid, Atiqa
    Aktas, Gulali
    PRIMARY CARE DIABETES, 2021, 15 (06) : 1071 - 1074